Azam L, Delamore I W
Br Med J. 1974 Dec 7;4(5944):560-4. doi: 10.1136/bmj.4.5944.560.
Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone. Nineteen new patients and nine who had escaped from previous single-agent therapy were included in the study. The results to date, on eight criteria of response, seem to be superior to those obtained from previous chemotherapeutic regimens. The study has been in progress for 18 months and only three patients have died. Only one who had not received previous therapy died, and she had complicating hyperparathyroidism, which almost certainly contributed to her death.
28例多发性骨髓瘤患者接受了由1,3-双(2-氯乙基)-1-亚硝基脲(卡莫司汀)、环磷酰胺、美法仑和泼尼松组成的四联化疗方案。该研究纳入了19例新患者和9例之前接受单药治疗后复发的患者。根据八项反应标准，目前的结果似乎优于之前化疗方案所取得的结果。该研究已进行了18个月，仅有3例患者死亡。仅1例未接受过先前治疗的患者死亡，她患有甲状旁腺功能亢进症，这几乎可以肯定是导致她死亡的原因。
